Polpharma has announced the integration of its Dutch Bioceros subsidiary under the Polpharma Biologics banner, to become “a truly integrated CDMO, offering the complete spectrum of services from discovery to commercial supply.”
Polpharma Biologics Integrates Bioceros
Company Plans To Retire The Bioceros Name Thereafter
Polpharma Biologics is making strategic moves to become a truly integrated CDMO by bringing its Dutch Bioceros subsidiary under the Polpharma Biologics brand.
More from Strategy
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.